publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
childrendiagnosi
treatment
chemoprophylaxi
institut
outbreak
manag
clinic
practic
guidelin
infecti
diseas
societi
america
clin
infect
di
treanor
j
influenza
vaccineoutmaneuv
antigen
shift
drift
n
engl
j
med
wright
pf
kirkland
kb
modlin
jf
consid
use
antibiot
treatment
influenzaassoci
pneumonia
n
engl
j
med
common
viral
lower
respiratori
tract
infect
rsv
human
rhinoviru
suchitra
rao
mbb
annchristin
nyquist
md
msph
paul
c
stillwel
md
rapid
hour
long
day
healthi
adult
shed
influenza
viru
day
young
children
may
shed
day
longer
gener
higher
viral
titer
influenza
occur
year
winter
earli
spring
associ
signific
morbid
mortal
certain
highrisk
popul
tabl
unit
state
death
per
year
attribut
influenza
peopl
year
age
account
death
influenza
respons
upper
respiratori
tract
infect
children
healthi
children
age
month
substanti
increas
risk
influenzarel
hospit
children
age
month
remain
increas
risk
influenzarel
clinic
emerg
depart
visit
hospit
less
younger
children
influenza
viru
infect
begin
attach
viral
ha
termin
sialic
acid
surfac
target
host
cell
lung
target
cell
influenza
viru
typic
ciliat
columnar
epitheli
alveolar
epitheli
cell
aec
ha
subtyp
display
uniqu
tropism
attach
influenza
viru
trigger
receptormedi
endocytosi
host
cell
thu
entri
cell
effect
releas
influenza
rna
cytosol
viral
form
ion
channel
viral
envelop
liber
viral
rna
travel
nucleu
infect
cell
messeng
rna
mrna
viral
rna
synthes
assembl
bud
daughter
virion
occur
cell
surfac
na
facilit
virion
releas
cleavag
sialic
acid
attach
viral
ha
without
cleavag
influenza
virion
aggreg
cell
surfac
releas
mechan
na
inhibitor
effect
ultim
viral
infect
lead
apoptosi
infect
epitheli
cell
denud
airway
result
acut
tracheobronch
type
aec
damag
tight
junction
alveolar
capillari
membran
allow
transud
fluid
protein
enter
alveolar
space
produc
acut
alveolar
damag
potenti
progress
acut
respiratori
distress
syndrom
ard
viral
ha
also
inhibit
resorpt
alveolar
fluid
epitheli
sodium
channel
promot
alveolar
edema
influenza
infect
result
cytokin
induct
also
activ
endotheli
pole
alveolar
capillari
barrier
facilit
neutrophil
influx
disrupt
barrier
function
host
immun
respons
influenza
infect
complex
redund
incorpor
innat
adapt
process
see
chapter
detail
innat
adapt
influenza
virus
envelop
ribonucl
acid
rna
virus
belong
famili
orthomyxovirida
three
viru
type
within
famili
influenza
b
c
influenza
b
virus
type
predominantli
infect
human
virus
respons
pandem
outbreak
influenza
annual
epidem
viru
contain
three
import
envelop
glycoprotein
hemagglutinin
ha
neuraminidas
na
matrix
protein
ha
viral
attach
protein
respons
entri
viru
cell
import
surfac
antigen
virusneutr
antibodi
direct
na
enzym
whose
main
function
facilit
celltocel
spread
viru
target
antivir
drug
zanamivir
oseltamivir
antibodi
ha
protect
infect
ill
antibodi
na
reduc
ill
sever
matrix
protein
structur
protein
link
viral
envelop
viru
core
integr
infect
influenza
virion
influenza
virus
segment
genom
contain
eight
strand
rna
properti
enabl
gene
reassort
occur
among
differ
subtyp
influenza
allow
new
subtyp
form
variat
structur
ha
na
influenza
virion
basi
subtyp
h
n
classif
nomenclatur
eg
influenza
fig
influenza
virus
develop
way
evad
bodi
immun
respons
use
antigen
variat
known
antigen
shift
drift
antigen
shift
seen
influenza
virus
result
replac
ha
occasion
na
novel
subtyp
nonhuman
influenza
virus
introduct
new
ha
human
virus
result
pandem
worldwid
epidem
potenti
caus
million
influenzarel
death
antigen
drift
result
accumul
mutat
within
antibodybind
site
ha
na
mutat
prevent
antibodi
previou
strain
effect
current
strain
enabl
spread
throughout
partial
immun
popul
antigen
drift
occur
influenza
b
virus
antigen
shift
drift
must
taken
account
strain
consid
inclus
annual
influenza
vaccin
humantohuman
transmiss
influenza
occur
smallparticl
aerosol
droplet
enter
environ
infect
individu
viru
bind
epitheli
cell
upper
lower
respiratori
tract
incub
period
exposur
ill
averag
day
keyword
influenza
respiratori
viru
respiratori
tract
ill
abstract
influenza
b
virus
orthomyxovirus
three
import
envelop
glycoprotein
hemagglutinin
ha
neuraminidas
na
matrix
protein
influenza
virus
develop
way
evad
bodi
immun
respons
use
antigen
variat
known
antigen
shift
replac
ha
na
antigen
novel
subtyp
noninfluenza
virus
drift
mutat
within
antibodybind
site
ha
na
new
influenza
virus
constantli
emerg
antigen
shift
drift
new
influenza
vaccin
requir
year
humantohuman
transmiss
influenza
occur
winter
earli
spring
smallparticl
aerosol
droplet
influenza
viru
attack
epitheli
cell
upper
lower
respiratori
tract
potenti
secondari
bacteri
infect
acut
respiratori
distress
syndrom
ard
symptom
influenza
infect
includ
fever
headach
cough
sore
throat
myalgia
nasal
congest
lower
respiratori
tract
manifest
pneumonia
bronchiol
virtual
indistinguish
viral
infect
children
certain
comorbid
chronic
lung
diseas
sever
neurolog
impair
higher
risk
influenzarel
complic
reliabl
test
influenza
revers
transcript
polymeras
chain
reaction
rtpcr
rapid
antigen
test
lower
sensit
specif
reliabl
period
low
influenza
activ
antivir
treatment
na
inhibitor
shorten
durat
fever
symptom
hospit
especi
start
within
hour
influenza
ill
onset
prevent
influenza
annual
influenza
vaccin
recommend
children
month
age
older
vaccin
contain
three
four
influenza
subtyp
chosen
depend
circul
strain
two
formul
approv
children
inactiv
influenza
vaccin
iiv
liveattenu
influenza
vaccin
laiv
although
children
year
age
consid
higher
risk
complic
influenza
highest
risk
younger
year
highest
hospit
death
rate
among
infant
younger
month
immun
respons
respons
infect
activ
macrophag
neutrophil
work
elimin
viral
particl
damag
apoptot
epitheli
cell
although
key
element
viral
elimin
recoveri
epitheli
integr
inflammatori
byproductssuch
myeloperoxidas
neutrophil
elastas
increas
nitric
oxid
synthasemay
caus
injuri
airway
increas
risk
secondari
bacteri
infect
may
due
delay
epitheli
heal
influenza
infect
excess
interferon
gamma
product
type
interferon
major
system
symptom
observ
acut
influenza
infect
attribut
cytokin
produc
releas
host
immun
respons
viremia
uncommon
immunocompet
host
similarli
dysfunct
nonrespiratori
organssuch
myocard
encephalopathi
enceph
rhabdomyolysisi
usual
associ
viral
infect
tissu
viral
infect
also
stimul
arm
immun
system
produc
thymic
stromal
lymphopoietin
tslp
tslp
stimul
dendrit
cell
induc
cell
predispos
host
allerg
airway
inflamm
asthma
stimul
type
cytokineproduc
innat
lymphoid
cell
synthes
promot
eosinophil
inflamm
excess
mucu
secret
bronchial
hyperrespons
may
explain
part
acut
influenza
infect
exacerb
asthma
potenti
subsequ
asthma
phenotyp
clinic
featur
great
overlap
symptomatolog
influenza
respiratori
pathogen
influenza
syndrom
usual
sudden
onset
associ
fever
headach
cough
sore
throat
myalgia
nasal
congest
weak
loss
appetit
retrospect
studi
adolesc
young
adult
influenzalik
ill
best
predictor
influenza
infect
cough
fever
posit
predict
valu
young
children
howev
less
classic
present
compar
adult
tend
higher
fever
less
promin
respiratori
symptom
gastrointestin
symptom
abdomin
pain
vomit
diarrhea
decreas
appetit
influenza
infect
also
import
caus
febril
seizur
lower
respiratori
tract
manifest
young
children
virtual
indistinguish
due
viral
infect
influenza
similar
respiratori
virus
may
caus
bronchiol
interstiti
pneumonia
laryngotrach
croup
bronchiti
exacerb
asthma
wheez
pneumonia
extrapulmonari
manifest
includ
myocard
hepat
enceph
myositi
renal
insuffici
syndrom
rhabdomyolysi
multiorgan
system
failur
find
examin
includ
tachypnea
conjunctiv
erythema
nasal
inject
edema
nasal
discharg
cervic
adenopathi
rash
uncommon
manifest
influenza
occur
usual
gener
maculopapular
rash
spare
palm
sole
rash
associ
influenza
infect
character
petechi
macular
papular
reticular
purpur
local
prurit
nonprurit
chest
radiograph
featur
influenza
pneumonia
indistinguish
pneumonia
caus
organ
common
radiograph
find
test
influenza
recommend
posit
neg
result
influenc
clinic
manag
clinic
practic
patient
test
consid
regardless
immun
statu
influenza
season
among
children
fever
acut
onset
respiratori
sign
symptom
acut
exacerb
underli
chronic
lung
diseas
infant
young
children
fever
sign
symptom
hospit
children
acut
respiratori
symptom
develop
acut
febril
respiratori
ill
sever
ill
children
fever
hypothermia
also
test
test
occur
time
year
children
epidemiolog
link
influenza
outbreak
eg
household
close
contact
peopl
suspect
influenza
return
travel
countri
influenza
virus
may
circul
particip
intern
mass
gather
cruis
ship
passeng
test
day
beyond
ill
onset
may
result
falseneg
test
result
decreas
viral
shed
occur
particular
among
older
children
test
modal
avail
includ
influenzaspecif
revers
transcript
polymeras
chain
reaction
rtpcr
multiplex
respiratori
pathogen
pcr
direct
fluoresc
antibodi
dfa
test
rapid
influenza
antigen
test
rtpcr
accur
test
modal
influenza
use
differenti
influenza
type
subtyp
significantli
sensit
rapid
influenza
antigen
detect
test
vs
respect
rapid
antigen
test
less
sensit
specif
rtpcr
test
metaanalysi
children
demonstr
sensit
influenza
influenza
b
studi
indic
rapid
antigen
test
reliabl
period
low
influenza
activ
immunofluoresc
antibodi
test
distinguish
influenza
b
respiratori
virus
howev
test
perform
depend
qualiti
respiratori
specimen
expertis
laboratori
viral
cultur
usual
unhelp
clinic
set
result
avail
hour
later
howev
help
confirm
screen
result
surveil
research
serolog
test
also
help
clinic
set
acut
convalesc
obtain
day
later
sera
requir
diagnosi
test
platform
includ
hemagglutinationinhibit
enzymelink
immunosorb
assay
elisa
complement
fixat
assay
fourfold
rise
greater
antibodi
titer
acut
convalesc
specimen
confirm
diagnosi
influenza
differenti
diagnosi
influenza
infect
list
tabl
clinic
trial
observ
data
show
earli
antivir
treatment
shorten
durat
fever
influenza
bilater
symmetr
perihilar
peribronchi
opac
focal
opac
asymmetr
diseas
may
also
occur
fig
lymph
node
enlarg
occur
pleural
effus
rare
nonspecif
find
make
challeng
differenti
viral
bacteri
pneumonia
base
radiograph
appear
alon
younger
children
influenza
pneumonia
may
bilater
patchi
opac
probabl
reflect
retent
mucu
progress
pneumonia
lead
diffus
airspac
diseas
ard
pictur
acut
respiratori
failur
complet
resolut
normal
chest
radiograph
expect
follow
mild
diseas
children
chronic
lung
diseas
asthma
airway
diseas
cardiovascular
diseas
neuromuscular
diseas
immunocompromis
state
highest
risk
complic
influenza
infect
see
tabl
sever
influenza
infect
present
bilater
pulmonari
infiltr
hypoxemia
lead
ard
death
particular
pandem
influenza
viru
associ
higher
rate
lifethreaten
lower
respiratori
tract
ill
includ
ard
thought
due
increas
predilect
infect
ciliat
epitheli
cell
lower
respiratori
tract
pneumonia
secondari
bacteri
infect
common
caus
hospit
influenza
although
streptococcu
pneumonia
common
pathogen
identifi
staphylococcu
aureu
commonli
associ
copathogen
methicillinresist
aureu
mrsa
coinfect
influenza
increasingli
identifi
risk
factor
mortal
previous
healthi
children
adolesc
clinic
featur
support
bacteri
superinfect
among
children
influenza
includ
secondari
fever
period
defervesc
focal
find
pulmonari
auscult
lobar
consolid
chest
imag
new
onset
respiratori
compromis
occur
sever
day
initi
symptom
neuraminidas
inhibitor
nai
oseltamivir
zanamivir
antivir
medic
still
recommend
treatment
chemoprophylaxi
influenza
influenza
b
viru
infect
owe
near
univers
suscept
inhibit
viral
na
enzym
help
progeni
escap
infect
cell
nai
may
also
efficaci
novel
influenza
virus
oseltamivir
given
oral
day
dose
adjust
requir
renal
impair
weight
tabl
common
side
effect
oseltamivir
nausea
andor
vomit
transient
neuropsychiatr
event
selfinjuri
delirium
report
mainli
among
japanes
adolesc
adult
zanamivir
dri
powder
administ
via
oral
inhal
fdaapprov
treatment
children
year
age
dose
two
breathactiv
inhal
twice
daili
day
prophylact
dose
two
inhal
daili
children
year
age
older
recommend
children
underli
airway
diseas
includ
asthma
owe
lack
safeti
efficaci
data
individu
seriou
advers
event
includ
bronchospasm
declin
lung
function
commonli
seen
patient
underli
airway
diseas
zanamivir
use
patient
underli
airway
diseas
instruct
shortact
bronchodil
avail
allerg
reaction
includ
rash
oropharyng
facial
edema
report
side
effect
includ
diarrhea
nausea
sinus
rhiniti
nasal
congest
bronchiti
cough
headach
dizzi
earnosethroat
complaint
peramivir
intraven
nai
indic
treatment
acut
uncompl
influenza
patient
year
age
older
symptomat
day
given
singl
administr
matrix
protein
inhibitor
amantadin
rimantadin
target
protein
potenti
effect
influenza
owe
lack
protein
channel
influenza
b
virus
antivir
medic
current
recommend
treatment
chemoprophylaxi
sinc
circul
influenza
strain
develop
resist
steroid
propos
adjunct
therapi
influenza
pneumonia
howev
sever
studi
fail
demonstr
clinic
benefit
treatment
patient
symptom
hospit
may
also
reduc
risk
complic
influenza
eg
otiti
media
young
children
pneumonia
respiratori
failur
death
clinic
benefit
greatest
antivir
treatment
administ
earli
especi
within
hour
influenza
ill
onset
treatment
wait
laboratori
confirm
influenza
start
soon
possibl
clinic
indic
antivir
treatment
recommend
regardless
day
ill
patient
confirm
suspect
influenza
hospit
sever
complic
progress
ill
outpati
higher
risk
influenza
complic
base
age
underli
medic
condit
clinic
judgmentbas
patient
diseas
sever
progress
age
underli
medic
condit
likelihood
influenza
time
sinc
onset
symptomsi
import
make
decis
regard
antivir
treatment
highrisk
outpati
antivir
treatment
may
consid
outpati
confirm
suspect
influenza
otherwis
healthi
treatment
initi
within
hour
ill
onset
american
academi
pediatr
recommend
oseltamivir
treatment
dose
mgkg
oral
twice
daili
infant
age
month
season
basi
data
indic
higher
dose
mgkg
need
achiev
protocoldefin
target
exposur
cohort
defin
capabl
acquisit
sustain
casg
studi
kimberlin
unknown
whether
higher
dose
improv
efficaci
prevent
develop
antivir
resist
howev
evid
dose
harm
caus
advers
event
infant
age
group
provid
familiar
potenti
manifest
egg
allergi
set
anaphylaxi
recogn
treat
children
observ
least
minut
sign
reaction
administr
vaccin
dose
nai
effect
prevent
influenza
yet
cdc
recommend
widespread
routin
use
chemoprophylaxi
owe
possibl
resist
virus
could
emerg
thu
limit
use
medic
highrisk
sever
ill
peopl
oseltamivir
use
chemoprophylaxi
influenza
among
infant
year
age
indic
although
owe
limit
data
age
group
children
less
month
age
receiv
prophylaxi
unless
situat
judg
critic
chemoprophylaxi
usual
recommend
hour
elaps
sinc
last
exposur
infect
person
effect
prophylaxi
antivir
medic
must
taken
day
durat
potenti
exposur
person
influenza
continu
day
last
known
exposur
postexposur
prophylaxi
consid
famili
member
close
contact
infect
patient
high
risk
complic
influenza
without
antivir
treatment
children
full
unev
recoveri
acut
uncompl
influenza
infect
unfortun
fatal
outcom
death
influenza
frequent
children
comorbid
asthma
sever
neurolog
impair
develop
ard
small
proport
children
may
develop
asthma
experienc
acut
influenza
infect
although
asthma
subsequ
infect
seem
sever
influenza
infect
furthermor
studi
indic
increas
overal
mortal
increas
incid
hospitalacquir
pneumonia
longer
durat
mechan
ventil
icu
stay
patient
treat
steroid
prevent
routin
annual
influenza
vaccin
recommend
children
month
age
older
ideal
vaccin
occur
onset
influenza
commun
administ
soon
vaccin
suppli
avail
vaccin
continu
long
influenza
virus
circul
multipl
differ
vaccin
formul
avail
licens
specif
age
group
appropri
particular
patient
popul
recommend
regard
influenza
vaccin
dose
updat
cdc
year
avail
via
center
diseas
control
prevent
cdc
influenza
websit
http
wwwcdcgovflu
also
publish
morbid
mortal
weekli
report
cdc
two
formul
vaccin
approv
children
inactiv
influenza
vaccin
iiv
liveattenu
influenza
vaccin
laiv
laiv
intranas
vaccin
offer
sole
quadrival
form
iiv
avail
trival
quadrival
formul
center
diseas
control
prevent
cdc
recommend
laiv
use
notic
due
low
vaccin
effect
influenza
season
recombin
influenza
vaccin
riv
avail
adult
egg
allergi
children
month
year
age
receiv
vaccin
first
time
requir
two
dose
vaccin
least
month
apart
influenza
vaccin
contraind
provid
tabl
data
demonstr
iiv
laiv
given
singl
ageappropri
dose
well
toler
virtual
recipi
egg
allergi
children
anaphylaxi
egg
may
receiv
influenza
vaccin
health
care
sever
allerg
reaction
compon
vaccin
includ
egg
protein
previou
dose
influenza
vaccin
moder
sever
ill
without
fever
histori
syndrom
within
week
receipt
influenza
vaccin
sever
allerg
reaction
compon
vaccin
moder
sever
ill
without
fever
histori
syndrom
within
week
receipt
influenza
vaccin
liveattenu
influenza
vaccin
laiv
sever
allerg
reaction
compon
vaccin
includ
egg
protein
previou
dose
influenza
vaccin
concomit
use
aspirin
aspirincontain
medic
children
adolesc
addit
advisori
committe
immun
practic
recommend
laiv
use
pregnant
women
immunosuppress
peopl
peopl
egg
allergi
children
age
year
asthma
wheez
episod
note
medic
record
within
past
month
parent
report
health
care
provid
state
wheez
asthma
within
last
month
moder
sever
ill
without
fever
histori
syndrom
within
week
receipt
influenza
vaccin
asthma
peopl
year
age
older
medic
condit
might
predispos
higher
risk
complic
attribut
influenza
harper
sa
bradley
js
englund
ja
et
al
season
influenza
adult
